Skip to content
Outliyr ← The Index board

Promising

Tesamorelin

The prediction game

Call it: rising or fading?

Where does Tesamorelin stand 12 months from now? Lock your call with a confidence level. When the window closes, the Brier rule scores your calibration: right and confident earns the most, wrong and confident costs the most. Points and a leaderboard spot are the whole prize. No stakes, no money.

Your 12-month call on Tesamorelin

New voice here? We send a one-tap verification link so every entry comes from a real person. Signed-in members skip this.

One call per intervention. It locks the moment you submit: no edits, no cancels. It resolves when the 12-month window closes.

The Crowd’s Call

Rising or fading over the next 12 months? Lock your call and find out if you saw it coming.

See the scout leaderboard: who called it first

Community Signal

No weigh-ins yet. Be the first and set the early signal.

Weigh in

Evidence

Evidence grade: A (strong evidence)

Graded from the strength of the published research, independent of any verdict on this page.

Evidence Anchor

BioHarmony 6.2/10

Tesamorelin is a 6.2 / 10 fit for body composition, hormonal, metabolic health, especially for readers who can match the protocol to HIV lipodystrophy context, IGF-1 monitoring, glucose risk, and prescription oversight. The best evidence anchors are [Badran et al. 2026](https://www.sciencedirect.com/science/article/abs/pii/S1871403X26000025), which Meta-analysis of 5 RCTs; found reductions in VAT, trunk fat, limb fat, hepatic fat percentage, and waist circumference, with increased lean body mass, and [Russo et al. 2024](https://journals.lww.com/aidsonline/fulltext/2024/10010/efficacy_and_safety_of_tesamorelin_in_people_with.4.aspx), which INSTI-regimen subgroup analysis; reductions in visceral fat, hepatic fat fraction, and trunk-to-appendicular fat ratio; below Track 1 size threshold. Tesamorelin is a stabilized GHRH analog that reduced visceral adipose tissue in the landmark [Falutz 2007](https://pubmed.ncbi.nlm.nih.gov/18057338/) HIV lipodystrophy Phase 3 trial and has newer support for hepatic fat reduction, but cost, daily injections, reversibility, cancer contraindications, and anti-doping prohibition keep the score at 6.6/10. ✅ Best for: Adults with HIV-associated abdominal lipodystrophy who fit the FDA-labeled indication and can access prescription Egrifta SV with clinician monitoring. Tesamorelin is also worth discussing for HIV-associated NAFLD or early MASH under hepatology or infectious-disease supervision, especially when liver fat is imaging-confirmed. Select older adults or MCI patients with low-normal IGF-1 may reasonably track the cognitive research, but cognition should remain secondary. Best-case users monitor IGF-1, HbA1c, fasting glucose, edema, arthralgia, retinopathy risk, and cancer history while using tesamorelin as part of a broader body composition and metabolic health plan. ❌ Avoid if: Avoid tesamorelin with active malignancy, prior malignancy without oncology clearance, pregnancy, trying to conceive, hypothalamic-pituitary disruption, severe or active diabetic retinopathy, poorly controlled diabetes, acute critical illness, or prior hypersensitivity to tesamorelin or mannitol. Competitive athletes should avoid tesamorelin because WADA prohibits growth hormone-releasing factors at all times. Also avoid tesamorelin if the goal is casual weight loss, rapid aesthetics, unmonitored longevity experimentation, or cheap gray-market peptide use. If you cannot commit to daily injections, lab monitoring, and months-long tracking, a lower-friction sleep or metabolic intervention is a better first move. Sourcing & dosing caveat: gray-market supply; score assumes clean, correctly-dosed material.

Read the full BioHarmony report

My score and my verdict: one signal of three, never the whole answer.

Momentum

Signals begin with Edition 2

Direction needs two weekly snapshots to compare, so the arrows stay off until the next edition. Attention tracking is already running.

In the news this week: Jay Campbell.

Momentum = how fast attention is rising across search, Reddit, PubMed, podcasts, and curated industry newsletters this week; it can flag an item as Overhyped/Fading, but it never overrides the evidence behind Proven. How momentum works.

Ring
Promising
Trend
Begins with Edition 2
Momentum
8.0%
BioHarmony Score
6.2/10
Last Updated
Jul 2, 2026

Sources

  • BioHarmony score
  • Search trend delta
  • Reddit velocity
  • PubMed publication count
  • Podcast mention frequency
  • Curated newsletter mentions

The score anchors the ring; the other five drive momentum, which can nudge the ring by one step at most. How placement works.

Weigh In

Your input feeds the community signal shown beside my verdict. It informs the board and it never sets the score by itself. How community input works.

Tried it in real life?

Which ring does it deserve?

New voice here? We send a one-tap verification link so every entry comes from a real person. Signed-in members skip this.